Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy in patients 5 years of age and older
Pioneering innovation aims to transform anticoagulant therapy and improve patient outcomes
The product will be manufactured at Lupin’s Chhatrapati Sambhajinagar facility in India
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
Subscribe To Our Newsletter & Stay Updated
